Table 2.

Unadjusted COPD-related outcomes and costs for patients receiving FSC versus AC

Outcome	FSC (n = 1078)	AC (n = 2923)	P value
Risk of COPD exacerbation (n, %)
Hospitalization	35 (3.3%)	168 (5.8%)	0.002
Emergency department visits	37 (3.4%)	171 (5.9%)	0.002
Phy+Rx	156 (14.5%)	448 (15.3%)	0.503
Hospitalization/emergency department visit	63 (5.8%)	307 (10.5%)	<0.001
Hospitalization/emergency department visit/Phy+Rx	200 (18.6%)	674 (23.1%)	0.002
Number of COPD exacerbations (mean, SD)
Hospitalization	0.04 (0.2)	0.07 (0.3)	<0.001
Emergency department visits	0.06 (0.4)	0.07 (0.4)	0.208
Phy+Rx	0.19 (0.6)	0.20 (0.6)	0.671
Hospitalization/emergency department visit	0.09 (0.5)	0.14 (0.5)	0.009
Hospitalization/emergency department visit/Phy+Rx	0.29 (0.8)	0.34 (0.8)	0.052
COPD-related annual costs (mean, SD)
Total costs	$1604 ($3187)	$1687 ($4299)	<0.001
Pharmacy costs	$934 ($814)	$684 ($724)	<0.001
Index drug	$636 ($612)	$397 ($471)	<0.001
Other study drug	$298 ($475)	$287 ($478)	0.529
Medical costs	$670 ($2923)	$1003 ($4095)	0.001
Hospitalization	$229 ($1983)	$453 ($3543)	0.001
Emergency department visit	$44 ($438)	$51 ($356)	0.003
Physician visit	$127 ($361)	$133 ($257)	0.335
Outpatient visit	$113 ($562)	$162 ($680)	0.014
Other	$158 ($1203)	$206 ($1126)	<0.001

Note: Bold values indicate statistically significant difference between cohorts (P < 0.050); all costs in USD.

Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; Phy+Rx, physician visit followed within 5 days by a prescription for an antibiotic or oral corticosteroid; SD, standard deviation.